Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Yingke Zhou, Xin Jin, Haixin Yu, Gengdu Qin, Penglin Pan, Jingyuan Zhao, Taoyu Chen, Xueyi Liang, Yan Sun, Bo Wang, Dianyun Ren, Shikai Zhu, Heshui Wu
Summary: This study reveals the role of HDAC5 in regulating the NF-KB signaling pathway and antitumor immune responses in PDAC. HDAC5 downregulation is associated with favorable prognosis in PDAC patients. HDAC5 regulates PD-L1 expression by interacting with NF-KB p65 and its inhibition sensitizes PDAC tumors to immune checkpoint blockade therapy.
Article
Immunology
Benjawan Wudtiwai, Kanchanok Kodchakorn, Thuzar Hla Shwe, Peraphan Pothacharoen, Thanyaluck Phitak, Raksa Suninthaboonrana, Prachya Kongtawelert
Summary: In this study, brazilein was found to reduce cell viability, induce apoptosis, and inhibit EMT and PD-L1 expression in breast cancer cells through suppression of phosphorylation of AKT, NF-kappa B, and GSK3 beta/beta-catenin signaling pathways. Moreover, brazilein also diminished migration ability by inhibiting MMP-9 and MMP-2 activation. Thus, brazilein might delay cancer progression and could be a potential therapeutic option in breast cancer patients with high levels of EMT and PD-L1.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Nutrition & Dietetics
Samia S. Messeha, Najla O. Zarmouh, Karam F. A. Soliman
Summary: Research on dietary polyphenolic compounds as antitumor agents is increasing due to the link between immunity and cancer. These compounds affect cancer progression and metastasis by inhibiting the EMT process, potentially reducing the risk of breast cancer.
Article
Immunology
Jichun Lin, Wenshuo Fang, Zhuo Xiang, Qingqing Wang, Huapeng Cheng, Shimin Chen, Jing Fang, Jia Liu, Qiang Wang, Zhimin Lu, Leina Ma
Summary: It has been found that glycolytic enzyme hexokinase 2 (HK2) plays a crucial role in upregulating PD-L1 expression in breast cancer cells. Under high glucose conditions, HK2 acts as a protein kinase and phosphorylates IκBa at T291, leading to the degradation of IκBa and activation of NF-κB, resulting in the promotion of PD-L1 expression. Correlation analysis shows that HK2 and PD-L1 expression levels are positively correlated with immune cell infiltration and survival time of breast cancer patients. These findings highlight the potential of targeting the protein kinase activity of HK2 for breast cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yanyan Zhang, Shuyi Zhu, Yuanyuan Du, Fan Xu, Wenbo Sun, Zhi Xu, Xiumei Wang, Peipei Qian, Qin Zhang, Jifeng Feng, Yong Xu
Summary: This study elucidates the molecular mechanism by which tumorous RelB contributes to immune evasion by inhibiting T cell immunity through the amplification of the PD-L1/PD-1-mediated immune checkpoint.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Shun-Wen Cheng, Po-Chih Chen, Min-Hsuan Lin, Tzong-Rong Ger, Hui-Wen Chiu, Yuan-Feng Lin
Summary: The study reveals that GBP5 is overexpressed in TNBC tissues, correlates with cellular migration ability, and serves as a poor prognostic marker. Co-expression analysis suggests that upregulation of GBP5 may be associated with the activation of interferon gamma and NF-kappa B signaling cascades, and is significantly positively correlated with PD-L1 expression in TNBC tissues.
Review
Biotechnology & Applied Microbiology
Xiaoli Hu, Jing Wang, Man Chu, Yi Liu, Zhi-wei Wang, Xueqiong Zhu
Summary: The ubiquitination and deubiquitination of PD-1/PD-L1 play crucial roles in modulating immune escape and tumor clearance, with abnormal ubiquitination influencing immune suppression. Targeting PD-1/PD-L1 ubiquitination may offer a promising therapeutic approach for cancer immunotherapy.
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Malina Xiao, Meriem Hasmim, Audrey Lequeux, Kris Van Moer, Tuan Zea Tan, Christine Gilles, Brett G. Hollier, Jean Paul Thiery, Guy Berchem, Bassam Janji, Muhammad Zaeem Noman
Summary: This study highlights the importance of CMTM6 and CMTM7 in regulating PD-L1 expression in aggressive breast cancer cells. Activating EMT process in breast cancer cells upregulates CMTM6, which is essential for cell surface expression of PD-L1. Dual targeting CMTM6 and CMTM7 can decrease PD-L1 surface expression, suggesting potential therapeutic benefits in highly aggressive breast cancer patients.
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Oncology
Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni, Sheng Chen
Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Genetics & Heredity
Ruyue Xu, Xinkuang Liu, Amin Li, Li Song, Jiaojiao Liang, Jiafeng Gao, Xiaolong Tang
Summary: The study found that c-Met regulates the transcription of PD-L1 through the MAPK/NF-kappa Bp65 pathway, thereby promoting the progress of HCC, and it is a potential target for the treatment of HCC.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2022)
Review
Cell Biology
Mateusz Kciuk, Damian Kolat, Zaneta Kaluzinska-Kolat, Mateusz Gawrysiak, Rafal Drozda, Ismail Celik, Renata Kontek
Summary: The application of immunotherapy for cancer treatment is expanding rapidly. Combining immunotherapeutic agents with different treatments can enhance the clinical response in patients who have developed resistance to monotherapy. Chemotherapeutic drugs that induce DNA damage often increase the expression of PD-L1, which can be used by cancer cells to evade immune surveillance. Targeting PD-L1 on cancer cells can restore the immune-reactive tumor microenvironment, making the tumor more susceptible to combined therapies. This review discusses the recent advances in understanding how DDR regulates PD-L1 expression and the impact of certain chemotherapeutic drugs on the anti-tumor immune response.
Review
Immunology
Hao Cai, Yichi Zhang, Jian Wang, Jinyang Gu
Summary: Macrophages can be categorized into M1 and M2 subsets, and reprogramming M2 to M1 macrophages has shown potential in cancer therapy. Key targets for reprogramming include CSF1, CSF1R, TLR7, TLR8, among others.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Dermatology
Charlee Nardin, Caroline Laheurte, Eve Puzenat, Laura Boullerot, Melanie Ramseyer, Amelie Marguier, Marion Jacquin, Yann Godet, Francois Aubin, Olivier Adotevi
Summary: This study demonstrates the clinical relevance of anti-telomerase Th1 response in patients with melanoma, showing an inverse correlation with disease progression and a predictive factor of response to immunotherapy. The presence of anti-TERT Th1 response is associated with improved progression-free survival and overall survival.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Chrystel Marton, Patricia Mercier-Letondal, Romain Loyon, Olivier Adotevi, Christophe Borg, Jeanne Galaine, Yann Godet
Summary: Engineered T-cell therapies have shown success in cancer, with stem cell memory and central memory T cells being more effective in antitumor activity. Using cord blood to generate minimally differentiated T-cell products may lead to more effective adoptive cancer immunotherapy by preserving less-differentiated T cells.
CANCER GENE THERAPY
(2022)
Review
Oncology
Myriam Ben Khelil, Yann Godet, Syrine Abdeljaoued, Christophe Borg, Olivier Adotevi, Romain Loyon
Summary: CD4(+) T cells play a crucial role in antitumor immunity, either by promoting or suppressing cytotoxic T cell responses. This review highlights the role of CD4(+) T subsets within the tumor microenvironment and discusses the latest developments in modulating CD4(+) T responses for cancer immunotherapy and improving cancer strategies.
Article
Multidisciplinary Sciences
Alizee Lebeau, Diane Bruyere, Patrick Roncarati, Paul Peixoto, Eric Hervouet, Gael Cobraiville, Bernard Taminiau, Murielle Masson, Carmen Gallego, Gabriel Mazzucchelli, Nicolas Smargiasso, Maximilien Fleron, Dominique Baiwir, Elodie Hendrick, Charlotte Pilard, Thomas Lerho, Celia Reynders, Marie Ancion, Roland Greimers, Jean-Claude Twizere, Georges Daube, Geraldine Schlecht-Louf, Francoise Bachelerie, Jean-Damien Combes, Pierrette Melin, Marianne Fillet, Philippe Delvenne, Pascale Hubert, Michael Herfs
Summary: This study reveals a new viral immune evasion strategy in which HPV infection leads to downregulation of host mucosal innate peptides, which are in turn used by predominant Lactobacillus species as amino acid source, ultimately causing an imbalance in the vaginal flora.
NATURE COMMUNICATIONS
(2022)
Editorial Material
Oncology
Olivier Adotevi, Jeanne Galaine
Summary: Treatment with CAR-T cells expressing chimeric antigen receptors shows promise as an anticancer therapy. However, its application to solid tumors has been limited. This study compares different anti-CD70 CAR-T cell clones and successfully develops a highly effective CAR-T cell candidate for treating renal cell carcinoma. The study emphasizes the influence of the CAR's single chain fragment variable on its efficacy and toxicity balance.
Article
Oncology
Blandine Cael, Jeanne Galaine, Isabelle Bardey, Chrystel Marton, Maxime Fredon, Sabeha Biichle, Margaux Poussard, Yann Godet, Fanny Angelot-Delettre, Christophe Barisien, Christophe Besiers, Olivier Adotevi, Fabienne Pouthier, Francine Garnache-Ottou, Elodie Bole-Richard
Summary: In this study, fresh or thawed umbilical cord blood (UCB) was used to produce CAR-T cells targeting CD123, and their functionality was compared to peripheral blood (PB) CAR-T cells. The results showed that UCB-derived CAR-T cells exhibited high transduction rate, activation status, and cytotoxic potential similar to PB-derived CAR-T cells. Moreover, UCB-derived CAR-T cells had a less differentiated profile than PB-derived CAR-T cells. These findings pave the way for the clinical development of UCB-derived CAR-T cells, which can be used in autologous or allogeneic settings to reduce post-transplant relapses and overcome HLA restrictions.
Article
Oncology
Olivier Adotevi, Dewi Vernerey, Pascale Jacoulet, Aurelia Meurisse, Caroline Laheurte, Hamadi Almotlak, Marion Jacquin, Vincent Kaulek, Laura Boullerot, Marine Malfroy, Emeline Orillard, Guillaume Eberst, Aurelie Lagrange, Laure Favier, Marie Gainet-Brun, Ludovic Doucet, Luis Teixeira, Zineb Ghrieb, Anne-Laure Clairet, Yves Guillaume, Marie Kroemer, Didier Hocquet, Melanie Moltenis, Samuel Limat, Elisabeth Quoix, Celine Mascaux, Didier Debieuvre, Christine Fagnoni-Legat, Christophe Borg, Virginie Westeel
Summary: The purpose of this study was to test the safety, immunogenicity, and efficacy of UCPVax vaccine in patients with metastatic non-small-cell lung cancer. The results showed that UCPVax vaccine was highly immunogenic and safe, and achieved interesting 1-year survival rate in advanced NSCLC patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Leila Fonderflick, Timothee Baudu, Olivier Adotevi, Michael Guittaut, Pascale Adami, Regis Delage-Mourroux
Summary: Vaccine therapy is a promising method of research to promote T cell immune response and to develop novel antitumor immunotherapy protocols. Increasing evidence shows that autophagy plays a role in antigen processing and presentation to T cells.
Article
Genetics & Heredity
Florestan Courant, Gwenola Bougras-Cartron, Caroline Abadie, Jean-Sebastien Frenel, Pierre-Francois Cartron
Summary: This study provides evidence supporting the idea that exposomes can generate genetic mutations by affecting DNA methylation/demethylation.